Flash Finance

Ajanta Pharma LimitedAJANTPHARMCorporate

Healthcare Drug Manufacturers - Specialty & Generic Latest results: Jun 2026 15 quarters of data
Consolidated Standalone
₹3,329.00
MCap ₹41,599 Cr · P/E 36.6
Ajanta Pharma Limited — Stock analysis & AI research Ajanta Pharma Limited — Multibagger AI analysis Ajanta Pharma Limited — Seasonality — best & worst months Ajanta Pharma Limited — Technical indicators & charts Ajanta Pharma Limited — Technical setup — score, trend, support & resistance Ajanta Pharma Limited — Live exchange announcements
📋 High ROE Stocks📋 High ROCE Stocks📋 High Operating Margin Stocks📋 High Interest Coverage Stocks📋 Stocks With Strong Quarterly Results📋 Low Debt Stocks ⚖️ vs Torrent Pharmaceuticals⚖️ vs Gland Pharma 🏭 Pharma sector
AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.
₹1,626 Cr
Sales · Jun 2026
+24.8% YoY
₹424 Cr
Operating Profit · Jun 2026
+20.6% YoY
26.1%
OPM % · Jun 2026
-3.3% YoY
₹334 Cr
Net Profit · Jun 2026
+30.9% YoY
₹26.75
EPS · Jun 2026
+30.9% YoY

📝 Ajanta Pharma Limited — results explained

Quarter ended June 2026 (Q1 FY27)

Ajanta Pharma Limited reported revenue of ₹1,626 crore for the quarter ended June 2026 (Q1 FY27), up 24.8% from ₹1,303 crore in the same quarter last year, and up 14.3% sequentially over the March 2026 quarter.

Net profit rose 30.9% year-on-year to ₹334 crore, from ₹255 crore. Earnings per share (EPS) came in at ₹26.75.

Operating profit stood at ₹424 crore — an operating margin (OPM) of 26.1%, compared with 27.0% in the year-ago quarter.

Full year and trailing twelve months

For the full year FY26, Ajanta Pharma Limited posted revenue of ₹5,453 crore, a growth of 17.3% over FY25, with a net profit of ₹1,056 crore (up 14.8% year-on-year).

On a trailing-twelve-month (TTM) basis, revenue stands at ₹5,777 crore with a net profit of ₹1,135 crore.

Valuation snapshot

At the current price of ₹3,329.00, AJANTPHARM has a market capitalisation of ₹41,599 crore and a trailing P/E of about 36.6.

Within the Drug Manufacturers - Specialty & Generic industry, it is the 16th-largest of the 31 companies we track by market value.

Shareholding pattern

As of Sep 2026, promoters held 63.47%, foreign institutional investors (FIIs) 7.63%, domestic institutional investors (DIIs) 21.94%, public shareholders 6.96% of Ajanta Pharma Limited.

Promoter holding slipped from 66.25% to 63.47% over the latest period.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close
Valuation
Market Cap ?
₹41,599 Cr
Current Price ?
₹3,329.0
P/E ?
36.65above ind
Industry P/E ?
35.00
P/B ?
9.19
P/S ?
7.20
P/FCF ?
246.15
Enterprise Value ?
₹41,859 Cr
EV/EBITDA ?
28.54
PEG ?
1.75
Earnings Yield ?
3.1%
Dividend Yield ?
0.85%
Profitability & Returns
Sales (TTM) ?
₹5,777 Cr
OPM ?
25.4%
Profit after tax (TTM) ?
₹1,135 Cr
EPS (TTM) ?
₹90.84
ROCE ?
32.0%
ROE ?
25.1%
ROA ?
18.4%
Growth
Sales — latest qtr ?
₹1,626 Cr
PAT — latest qtr ?
₹334 Cr
YoY qtr sales growth ?
24.8%
YoY qtr profit growth ?
30.9%
Sales growth (3y) ?
13%
Sales growth (5y) ?
14%
Profit growth (3y) ?
21%
Profit growth (5y) ?
10%
Financial Health
Debt ?
₹260 Cr
Debt to Equity ?
0.06
Interest Coverage ?
77.6
Current Ratio ?
N/A
Ownership
Promoter holding ?
63.47%
Change in promoter holding ?
-2.79%
Pledged percentage ?
N/A
Market
Return 3 months ?
-2.6%
Return 6 months ?
19.3%

🗓️ Quarterly results (15 quarters · ₹ Cr)

same fiscal quarter as Jun bestweakest per row · for costs (interest, NPAs) low is best
Metric Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026 YoY % QoQ %
Sales 9728821,0211,0281,1051,0541,1451,1871,1461,1701,3031,3541,3751,4221,626 +24.8% +14.3%
Operating Profit 170149271291314278330311321297351328382333424 +20.6% +27.2%
Other Income 353732211436261930182659256171 +169.3% +16.2%
Interest 311222168653523 -39.5% +59.0%
Depreciation 333333343434343436404143444544 +7.8% -1.1%
Profit Before Tax 168152269276291278322290307269331341359347447 +34.9% +28.8%
Net Profit 135122208195210203246216233225255260274267334 +30.9% +25.2%
EPS 10.509.5416.5315.5116.6816.1019.5417.2718.6018.0020.4420.8321.9121.3526.75 +30.9% +25.3%
OPM % 17.4% 16.9% 26.6% 28.3% 28.4% 26.4% 28.9% 26.2% 28.0% 25.4% 27.0% 24.2% 27.8% 23.4% 26.1% -3.3% +11.5%

📆 Annual results (₹ Cr, FY = Apr–Mar)

Metric FY25 FY26 TTM YoY %
Sales ₹4,648 Cr ₹5,453 Cr ₹5,777 Cr +17.3%
Operating Profit ₹1,260 Cr ₹1,394 Cr ₹1,467 Cr +10.7%
OPM % 27.10% 25.57% 25.39% -5.6%
NPM % 19.80% 19.37% 19.65% -2.2%
Other Income ₹94 Cr ₹172 Cr ₹216 Cr +81.6%
Depreciation ₹144 Cr ₹173 Cr ₹176 Cr +19.9%
Interest ₹21 Cr ₹16 Cr ₹14 Cr -24.0%
EBIT ₹1,115 Cr ₹1,222 Cr ₹1,291 Cr +9.5%
PBT ₹1,189 Cr ₹1,378 Cr ₹1,493 Cr +15.8%
Tax ₹269 Cr ₹241 Cr ₹278 Cr -10.2%
Net Profit ₹920 Cr ₹1,056 Cr ₹1,135 Cr +14.8%
EPS ₹73.41 ₹84.53 ₹90.84 +15.1%
Material Cost ₹1,096 Cr ₹818 Cr ₹923 Cr -25.4%
Employee Cost ₹1,090 Cr ₹950 Cr ₹1,029 Cr -12.8%
Extraordinary Items — — — —

🏛️ Balance Sheet (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Equity Capital 25252525 +0.0%
Reserves 3,3633,5423,7654,502 +19.6%
Borrowings 363547260 +453.2%
Other Liabilities 1,1599271,0671,368 +28.2%
Total Liabilities 4,5824,5304,9046,155 +25.5%
Fixed Assets 1,4961,4791,7621,867 +6.0%
CWIP 209256176258 +46.6%
Investments 535349464588 +26.7%
Other Assets 2,3412,4462,5023,441 +37.5%
Total Assets 4,5824,5304,9046,155 +25.5%

💧 Cash Flow (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Cash from Operating Activity 7927851,157529 -54.3%
Cash from Investing Activity -56065-377-429 -13.8%
Cash from Financing Activity -108-1,051-733-168 +77.1%
Net Cash Flow 124-20147-68 -244.7%
Free Cash Flow 618646840169 -79.9%
CFO/OP 117%94%117%64% -45.3%

➗ Ratios (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Debtor Days 10310893124 +33.3%
Inventory Days 283283308289 -6.2%
Days Payable 147159155168 +8.4%
Cash Conversion Cycle 240233246246 +0.0%
Working Capital Days 8311997148 +52.6%
ROCE % 23%32%32%32% +0.0%

👥 Shareholding (latest 5 periods)

Metric Jun 2025Sep 2025Dec 2025Mar 2026Sep 2026 % Chg
Promoters 66.26%66.25%66.25%66.25%63.47% -4.2%
FIIs 8.86%8.53%7.97%8.26%7.63% -7.6%
DIIs 17.50%17.90%18.58%18.36%21.94% +19.5%
Government 0.01%0.01%0.01%0.01%— —
Public 7.38%7.32%7.20%7.14%6.96% -2.5%
No. of Shareholders 68,88267,78565,40967,95561,923 -8.9%

⚖️ Peer comparison

Industry: Drug Manufacturers - Specialty & Generic · top 25 of 31 companies · full page →
# Company CMP MCap (Cr) P/E Sales TTM NP TTM OPM% NPM% Sales YoY% NP YoY% Qtr Rev Δ% Qtr NP Δ%
1 SUNPHARMA Sun Pharmaceutical ₹1,840.00 441,478 36.5 59,911 12,104 29.8% 20.2% 11.2% 5.1% 10.5% 27.0%
2 DIVISLAB Divi's Laboratories ₹9,235.00 245,160 83.8 11,230 2,925 35.3% 26.0% 12.8% 16.7% 27.8% 65.5%
3 TORNTPHARM Torrent Pharmaceuticals ₹4,931.00 187,559 87.1 15,723 2,156 33.0% 13.7% 21.4% 11.9% 54.8% 3.3%
4 ZYDUSLIFE Zydus Lifesciences ₹1,162.20 115,930 23.2 27,148 5,070 31.2% 18.7% 16.8% 12.0% 16.2% 14.5%
5 CIPLA Cipla ₹1,366.00 110,353 32.7 28,324 3,356 18.7% 11.8% 2.2% -26.7% 2.3% -39.2%
6 LAURUSLABS Laurus Labs ₹1,969.00 106,387 97.2 7,270 1,090 28.0% 15.0% 22.7% 147.9% 29.1% 123.9%
7 DRREDDY Dr. Reddy's ₹1,165.50 97,085 29.3 28,704 3,273 15.3% 11.4% -10.4% -25.8% -5.6% -69.2%
8 AUROPHARMA Aurobindo Pharma ₹1,679.80 96,652 26.2 34,935 3,711 20.3% 10.6% 6.1% 0.6% 16.3% 25.2%
9 LUPIN Lupin ₹2,095.00 95,797 17.9 27,958 5,356 31.5% 19.2% 23.1% 62.0% 31.9% 87.8%
10 MANKIND Mankind Pharma ₹2,280.00 94,174 46.1 14,738 2,067 26.0% 14.0% 16.3% -3.7% 12.9% 29.1%
11 GLENMARK Glenmark Pharmaceuticals ₹2,419.20 68,276 38.0 17,737 1,797 27.0% 10.1% -61.2% -67.4% 23.1% 927.9%
12 ALKEM Alkem Laboratories ₹5,243.50 62,694 29.1 15,081 2,187 20.1% 14.5% 13.5% 7.6% 10.9% -21.6%
13 ABBOTINDIA Abbott India ₹25,860.00 54,951 34.0 7,005 1,615 28.1% 23.1% 8.1% 9.7% 4.4% 17.2%
14 IPCALAB Ipca Laboratories ₹1,964.20 49,833 38.0 10,125 1,379 22.0% 13.6% 7.9% 55.0% 20.8% 82.2%
15 GLAND Gland Pharma ₹2,935.90 48,433 47.1 6,431 1,028 25.3% 16.0% -64.7% -48.4% 22.3% 96.7%
16 AJANTPHARM Ajanta Pharma ₹3,398.90 42,472 37.4 5,777 1,135 25.4% 19.7% 17.3% 14.8% 24.8% 30.9%
17 JBCHEPHARM J. B. ₹2,416.10 38,793 53.4 4,148 709 26.7% 17.1% 5.9% 7.5% -4.8% -30.7%
18 EMCURE EMCURE PHARMACEUTICALS ₹1,975.10 37,470 37.0 9,684 1,019 20.4% 10.5% 16.6% 33.1% 22.8% 36.0%
19 WOCKPHARMA Wockhardt ₹2,021.50 32,848 92.5 3,133 353 19.9% 11.3% -2.3% 342.1% 25.9% 199.1%
20 NEULANDLAB Neuland Laboratories ₹23,455.00 30,093 82.7 2,023 365 28.4% 18.0% 37.0% 40.2% 136.3% 666.0%
21 PPLPHARMA Piramal Pharma ₹211.50 28,024 113.5 9,206 247 11.0% 2.7% -3.1% -37.9% 17.4% -161.3%
22 GRANULES Granules India ₹885.60 21,945 32.8 5,633 663 22.7% 11.8% 19.7% 18.8% 22.0% 59.3%
23 CAPLIPOINT Caplin Point ₹2,752.60 20,923 31.4 2,287 678 34.8% 29.7% 12.9% 20.2% 19.6% 18.8%
24 ERIS Eris Lifesciences ₹1,358.00 18,820 29.0 3,230 666 35.2% 20.6% 8.2% 72.6% 13.0% 14.6%
25 ASTRAZEN AstraZeneca Pharma ₹6,755.00 16,888 99.6 2,432 170 9.4% 7.0% 32.7% 62.1% 29.7% -32.1%
❓ Frequently asked questions
What was Ajanta Pharma Limited's revenue in Q1 FY27?
Ajanta Pharma Limited reported revenue of ₹1,626 crore for the quarter ended June 2026 (Q1 FY27), up 24.8% from ₹1,303 crore in the same quarter last year, and up 14.3% sequentially over the March 2026 quarter.
What was Ajanta Pharma Limited's net profit in Q1 FY27?
Net profit rose 30.9% year-on-year to ₹334 crore, from ₹255 crore. Earnings per share (EPS) came in at ₹26.75.
What is AJANTPHARM's market capitalisation and P/E ratio?
At the current price of ₹3,329.00, AJANTPHARM has a market capitalisation of ₹41,599 crore and a trailing P/E of about 36.6.
Who owns Ajanta Pharma Limited? (shareholding pattern)
As of Sep 2026, promoters held 63.47%, foreign institutional investors (FIIs) 7.63%, domestic institutional investors (DIIs) 21.94%, public shareholders 6.96% of Ajanta Pharma Limited.
TTM ends 2026-06-30. Amounts are ₹ crore unless stated otherwise. Figures are extracted by AI from public quarterly filings; gaps are filled from public market data. Live price refreshed about twice a day from exchange data. Educational information only — not financial advice.
⚠️ How this site is made: Market data pages are computed automatically from NSE/BSE publications and company filings; news articles and announcement analyses are written with AI assistance, with a human in the loop: our editors review what the AI produces. Both can contain errors. Verify with the original sources before any investment decision. Not investment advice; Flash Finance is not SEBI-registered. How we use AI